Target Discovery validates and utilizes protein isoforms for clinical diagnosis and management of diseases. The company's Isonostic products make isoform biomarker information accessible to clinicians. Based in Palo Alto, Calif., its other technologies include stable isotope mass spectrometric techniques for glycan analysis and protein identification method resolve and measure protein isoform biomarkers by mass spectrometry and capillary electrophoresis. In addition, Target Discovery's Isonostic Assays assist in the diagnostic applications beyond cancer. In addition, its Isonostic products address cancer aggressiveness, and chemotherapy selection in breast and ovarian cancer.